Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non–alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Algernon Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AGN is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AGN's weekly volatility has decreased from 25% to 13% over the past year.
7 Day Return
1 Year Return
Return vs Industry: AGN exceeded the Canadian Pharmaceuticals industry which returned 18.9% over the past year.
Return vs Market: AGN exceeded the Canadian Market which returned 0.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Algernon Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StWe're Hopeful That Algernon Pharmaceuticals (CSE:AGN) Will Use Its Cash Wisely
8 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Algernon Pharmaceuticals Inc.'s (CSE:AGN) Shareholder Register?
1 year ago | Simply Wall StHere's Why We're A Bit Worried About Algernon Pharmaceuticals's (CNSX:AGN) Cash Burn Situation
Is Algernon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AGN is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: AGN is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGN is overvalued based on its PB Ratio (3.5x) compared to the CA Pharmaceuticals industry average (1.7x).
How is Algernon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Algernon Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Algernon Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Algernon Pharmaceuticals competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Algernon Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGN is currently unprofitable.
Growing Profit Margin: AGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGN is unprofitable, but has reduced losses over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare AGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).
Return on Equity
High ROE: AGN has a negative Return on Equity (-44.77%), as it is currently unprofitable.
How is Algernon Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AGN's short term assets (CA$9.4M) exceed its short term liabilities (CA$1.1M).
Long Term Liabilities: AGN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AGN is debt free.
Reducing Debt: AGN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AGN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 19.5% each year.
What is Algernon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Moreau (55 yo)
Mr. Christopher J. Moreau, also known as Chris, has been Chief Executive Officer at Algernon Pharmaceuticals Inc. (f.k.a. Breathtec Biomedical Inc.) since March 1, 2018 and serves its Director since May 13...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD83.48K) is below average for companies of similar size in the Canadian market ($USD166.28K).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
|CEO & Director||2.75yrs||CA$108.00k||0.64% |
|CFO & Director||5.17yrs||CA$48.00k||0.19% |
|Chief Science Officer||2.17yrs||CA$138.49k||no data|
Experienced Management: AGN's management team is considered experienced (2.8 years average tenure).
|CEO & Director||2.75yrs||CA$108.00k||0.64% |
|CFO & Director||5.17yrs||CA$48.00k||0.19% |
|Member of Business Advisory Board||0.67yr||no data||no data|
|Member of Medical & Scientific Advisory Board||1.75yrs||no data||no data|
|Independent Director||5.17yrs||no data||0.71% |
|Independent Director||5.17yrs||no data||no data|
|Member of Medical & Scientific Advisory Board||1.67yrs||no data||no data|
|Member of Medical & Scientific Advisory Board||1yr||no data||no data|
|Member of Medical & Scientific Advisory Board||0.83yr||no data||no data|
|Member of Medical and Scientific Advisory Board||0.17yr||no data||no data|
Experienced Board: AGN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 95.3%.
Algernon Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Algernon Pharmaceuticals Inc.
- Ticker: AGN
- Exchange: CNSX
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$49.747m
- Shares outstanding: 140.13m
- Website: https://algernonpharmaceuticals.com
- Algernon Pharmaceuticals Inc.
- 700 West Pender Street
- Suite 915
- British Columbia
- V6C 1G8
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AGN||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Feb 2016|
|AGW||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Feb 2016|
|AGNP.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Feb 2016|
Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non–alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease,...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/02 23:42|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.